LINCOLNPharmaceuticals
Lincoln Pharmaceuticals Ltd — Cash Flow Statement
₹564.95
-2.30%
Lincoln Pharmaceuticals Ltd Cash Flow Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Free Cash Flow | 73.77 Cr | 23.60 Cr | 24.98 Cr | 30.61 Cr | — |
| Repayment Of Debt | -69.42 Cr | -20.90 Cr | -19.50 Cr | -0.52 Cr | — |
| Issuance Of Debt | 68.42 Cr | 20.00 Cr | 19.36 Cr | 2.00 Cr | — |
| Capital Expenditure | -19.24 Cr | -39.61 Cr | -14.28 Cr | -45.53 Cr | — |
| End Cash Position | 13.41 Cr | 5.75 Cr | 5.05 Cr | 6.93 Cr | — |
| Beginning Cash Position | 5.75 Cr | 5.05 Cr | 6.93 Cr | 11.44 Cr | — |
| Changes In Cash | 7.67 Cr | 0.70 Cr | -1.88 Cr | -4.50 Cr | — |
| Financing Cash Flow | -6.40 Cr | -5.18 Cr | -4.50 Cr | -2.56 Cr | — |
| Interest Paid Cff | -1.80 Cr | -1.27 Cr | -1.35 Cr | -1.04 Cr | — |
| Cash Dividends Paid | -3.61 Cr | -3.00 Cr | -3.00 Cr | -3.00 Cr | — |
| Net Issuance Payments Of Debt | -1.00 Cr | -0.90 Cr | -0.14 Cr | 1.48 Cr | — |
| Net Short Term Debt Issuance | -1.00 Cr | -0.90 Cr | -0.14 Cr | 2.00 Cr | — |
| Short Term Debt Payments | -69.42 Cr | -20.90 Cr | -19.50 Cr | 0.00 | — |
| Short Term Debt Issuance | 68.42 Cr | 20.00 Cr | 19.36 Cr | 2.00 Cr | — |
| Investing Cash Flow | -78.95 Cr | -57.34 Cr | -36.64 Cr | -78.08 Cr | — |
| Net Other Investing Changes | -1.25 Cr | 21.55 Cr | -15.02 Cr | -10.76 Cr | — |
| Interest Received Cfi | 3.70 Cr | 8.99 Cr | 0.93 Cr | 2.63 Cr | — |
| Dividends Received Cfi | 0.09 Cr | 44000.00 | — | 0.00 | 0.03 Cr |
| Net Investment Purchase And Sale | -28.68 Cr | -24.80 Cr | 10.61 Cr | -12.53 Cr | — |
| Sale Of Investment | 56.45 Cr | 74.83 Cr | 73.80 Cr | 40.52 Cr | — |
| Purchase Of Investment | -85.14 Cr | -99.63 Cr | -63.19 Cr | -53.05 Cr | — |
| Net Intangibles Purchase And Sale | -0.21 Cr | -0.14 Cr | -0.02 Cr | — | — |
| Purchase Of Intangibles | -0.21 Cr | -0.14 Cr | -0.02 Cr | — | — |
| Net PPE Purchase And Sale | -18.91 Cr | -39.39 Cr | -13.55 Cr | -45.45 Cr | — |
| Sale Of PPE | 0.12 Cr | 0.09 Cr | 0.71 Cr | 0.08 Cr | — |
| Purchase Of PPE | -19.03 Cr | -39.48 Cr | -14.26 Cr | -45.53 Cr | — |
| Operating Cash Flow | 93.02 Cr | 63.22 Cr | 39.26 Cr | 76.13 Cr | — |
| Taxes Refund Paid | -26.31 Cr | -26.15 Cr | -29.61 Cr | -23.70 Cr | — |
| Change In Working Capital | 9.17 Cr | -16.12 Cr | -31.37 Cr | 2.40 Cr | — |
| Change In Other Current Liabilities | 5.14 Cr | 0.07 Cr | 1.30 Cr | -1.87 Cr | — |
| Change In Other Current Assets | -5.92 Cr | -4.21 Cr | 4.37 Cr | 18.28 Cr | — |
| Change In Payable | 12.51 Cr | 21.57 Cr | -20.51 Cr | 14.59 Cr | — |
| Change In Inventory | -1.51 Cr | -7.14 Cr | 2.71 Cr | -26.13 Cr | — |
| Change In Receivables | -4.78 Cr | -26.09 Cr | -20.21 Cr | -3.12 Cr | — |
| Other Non Cash Items | -5.34 Cr | -5.56 Cr | -4.14 Cr | -3.58 Cr | — |
| Provisionand Write Offof Assets | -0.29 Cr | 0.65 Cr | -0.18 Cr | -0.17 Cr | — |
| Depreciation And Amortization | 12.90 Cr | 10.62 Cr | 9.17 Cr | 8.09 Cr | — |
| Depreciation | 12.90 Cr | 10.62 Cr | 9.05 Cr | 7.95 Cr | — |
| Gain Loss On Investment Securities | -6.89 Cr | -22.75 Cr | -5.01 Cr | -3.68 Cr | — |
| Gain Loss On Sale Of PPE | 0.14 Cr | 0.28 Cr | -0.08 Cr | 0.13 Cr | — |
| Net Income From Continuing Operations | 109.19 Cr | 122.24 Cr | 100.48 Cr | 95.94 Cr | — |
| Amortization Cash Flow | — | 0.11 Cr | 0.11 Cr | 0.14 Cr | 0.14 Cr |
| Common Stock Dividend Paid | — | — | — | -3.00 Cr | 0.00 |
| Net Long Term Debt Issuance | — | — | — | -0.52 Cr | -0.72 Cr |
| Long Term Debt Payments | — | — | — | -0.52 Cr | -0.72 Cr |
| Net Business Purchase And Sale | — | — | — | 0.00 | 0.05 Cr |
| Sale Of Business | — | — | — | 0.00 | 0.05 Cr |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Lincoln Pharmaceuticals Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.